NCT02786953

Brief Summary

Adolescents with type 1 diabetes (T1D) are at increased risk for problems with adherence and suboptimal glycemic control, and novel approaches are needed to improve outcomes in this high-risk population. The majority of adolescents obtain insufficient sleep (defined as \<8 hours/night), and sleep disturbance has been significantly associated with poorer adherence and predicted greater problems with quality of life and worse glycemic control. Yet, no interventions have addressed sleep in youth with T1D. Working from a biopsychosocial and contextual model of sleep, the investigators propose to tailor a sleep-promoting intervention to meet the needs of adolescents with T1D by conducting interviews with to identify the barriers and facilitators to adequate sleep specific to this population. The sleep-promoting intervention will be developed and tested, building on successful sleep interventions in other populations, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, while addressing the needs unique to adolescents with T1D, such as fear of hypoglycemia. The study will be conducted by a multidisciplinary team, consisting of Sarah Jaser, PhD, a pediatric psychologist, and two co-investigators, Beth Malow, MD, MS, a neurologist with specialty in sleep medicine, and Jill Simmons, MD, a pediatric endocrinologist. Sleep is a potentially modifiable risk factor that may have both a physiological and behavioral impact on diabetes outcomes. Given the strong associations between sleep and diabetes outcomes in the preliminary data, and recent evidence from sleep restriction studies indicating the impact of insufficient sleep on insulin sensitivity, behavior, and mood, there is reason to believe that a sleep-promoting intervention has the potential to improve outcomes in adolescents with T1D indirectly by improving adherence and directly through its effect on metabolic function. Therefore, the proposed study offers a novel approach to improve adherence, quality of life, and glycemic control in adolescents with T1D.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 18, 2016

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 1, 2016

Completed
1.4 years until next milestone

Study Start

First participant enrolled

October 19, 2017

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 5, 2019

Completed
9 months until next milestone

Results Posted

Study results publicly available

October 18, 2019

Completed
Last Updated

January 18, 2020

Status Verified

January 1, 2020

Enrollment Period

1 year

First QC Date

May 18, 2016

Results QC Date

September 16, 2019

Last Update Submit

January 6, 2020

Conditions

Keywords

SleepAdherenceDiabetes ManagementAdolescent

Outcome Measures

Primary Outcomes (6)

  • Sleep Quality: Baseline

    Sleep quality will be measured with the Pittsburgh Sleep Quality Index total score. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.

    baseline

  • Sleep Quality 3 Months

    Sleep quality will be measured with the Pittsburgh Sleep Quality Index total score. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.

    3 months

  • Glycemic Control (HbA1c) Baseline

    HbA1C is a measure of average blood glucose levels. It is measured quarterly at regular clinic visits.

    Baseline

  • Glycemic Control (HbA1c) 3 or 6 Months

    HbA1C is a measure of average blood glucose levels. It is measured quarterly at regular clinic visits.

    3 months or 6 months

  • Sleep Duration: Baseline

    Sleep duration will be measured with actigraphy (total sleep time)

    baseline

  • Sleep Duration: 3 Months

    Sleep duration will be measured with actigraphy (total sleep time)

    3 months

Secondary Outcomes (3)

  • Quality of Life (PedsQL)

    Baseline and 3 months

  • Adherence (Self Care Inventory) Parent

    Baseline and 3 months

  • Adherence (Self Care Inventory) Teen

    Baseline and 3 months

Study Arms (2)

Sleep Promotion

EXPERIMENTAL

Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.

Behavioral: Sleep Promotion

Usual Care

NO INTERVENTION

Usual Care

Interventions

Sleep PromotionBEHAVIORAL

Behavioral intervention to improve sleep quality and duration.

Sleep Promotion

Eligibility Criteria

Age13 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Diagnosed with type 1 diabetes for at least 12 months
  • Speak and read English
  • Report Insufficient sleep (\< 8 hours/night most school nights)

You may not qualify if:

  • Other major health problems or sleep disorders (other than insomnia)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Limitations and Caveats

pilot study with small sample size

Results Point of Contact

Title
Sarah S Jaser
Organization
Vanderbilt University Medical Center

Study Officials

  • Sarah S Jaser, PhD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 18, 2016

First Posted

June 1, 2016

Study Start

October 19, 2017

Primary Completion

October 23, 2018

Study Completion

February 5, 2019

Last Updated

January 18, 2020

Results First Posted

October 18, 2019

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will not share

Locations